ClinicalTrials.gg
CompletedNCT02517619EGP-437-006Updated Jul 26, 2018

Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis

A Phase 3 interventional study of Dexamethasone Phosphate Ophthalmic Solution and Prednisolone Acetate Ophthalmic (1%) in Anterior Uveitis, sponsored by Eyegate Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 12 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-07-26.

Sponsored by Eyegate Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
251
Allocation
Randomized
Ages
12 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Uveitis, Anterior with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Uveitis, Anterior · United States.

Enrollment
Largest of 27
251 · median 40
Started
2016
with 2 others
Phase 3
9 of 30
none open now
Registered
14th of 30
by date
Lead sponsor
3 of 30
Eyegate Pharmaceuticals, Inc.

Among the 30 studies in Uveitis, Anterior with a site in United States, this one has the largest enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2016, is one of 9 in phase 3, and was the 14th registered.

Uveitis, Anterior

56 studies on the registry are indexed under Uveitis, Anterior; 9 are open to participants now.

Browse Uveitis, Anterior studies →

Open to participants now

5 of the 30 studies in Uveitis, Anterior with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Uveitis, Anterior studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 12 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Uveitis, Anterior with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.

Read the detailed description

This will be a Phase 3, randomized, double-masked, parallel arm, positive-controlled non-inferiority study, in which up to 250 subjects (approximately 125 subjects per treatment arm) will be enrolled at up to 60 clinical sites. Patients with non-infectious anterior segment uveitis who are interested in participating in the study will be provided an informed consent form prior to screening. Screening/Baseline procedures which include BCVA, slit lamp examination, fundus exam, IOP by tonometry will be used to determine eligibility.

03

Conditions studied

  • Anterior Uveitis

Browse trials for

Keywords

  • Iontophoresis
  • Ophthalmology
  • Non-Infectious Anterior Segment Uveitis
04

Who can participate

Ages eligible
12 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age 12 to 85 years with a diagnosis of non-infectious anterior segment uveitis defined as an AC cell count of ≥ 11 cells
  2. Receive, understand, and sign a copy of the written form
  3. Be able to return for all study visits and willing to comply with all study-related instructions

Exclusion criteria

Exclusion Criteria:

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
251 participants (actual)

Study arms

  • Experimental
    Dexamethasone Phosphate Ophthalmic Solution

    Dexamethasone phosphate ophthalmic solution (40 mg/mL)

    Drug: Dexamethasone Phosphate Ophthalmic Solution

  • Active comparator
    Prednisolone Acetate Ophthalmic (1%)

    Prednisolone Acetate Ophthalmic (1%)

    Drug: Prednisolone Acetate Ophthalmic (1%)

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with an AC cell count of zero at Day 14

    Time frame: Day 14 ± 2 days

07

Study locations

1 site
  • Virginia Eye Consultants
    Norfolk, Virginia 23502, United States
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2016 to primary completion in Apr 2018, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2015
First posted
Aug 7, 2015
StartActual
Jan 16, 2016
Primary completionActual
Apr 20, 2018
CompletionActual
May 29, 2018
Last update
Jul 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02517619
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Aug 7, 2015
Start date
Jan 16, 2016
Primary completion
Apr 20, 2018
Completion
May 29, 2018
Last update
Jul 26, 2018

Study contacts

John D. Sheppard, M.D.
principal investigator · Study Principal Investigator

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone phosphate

Start the discussion